Form 4: Aptevo Director Zsolt Harsanyi Granted RSUs

Aptevo Therapeutics Director Zsolt Harsanyi was granted 7,200 Restricted Stock Units, vesting on the first anniversary of the grant date.

Summary

• Zsolt Harsanyi, a Director of Aptevo Therapeutics Inc. (APVO), was granted 7,200 Restricted Stock Units (RSUs).
• The grant date for these RSUs was August 6, 2025.
• Each RSU converts into one share of common stock, with a par value of $0.001 per share.
• The RSUs will vest in full on the first anniversary of the grant date, which is August 6, 2026.
• Following this transaction, Mr. Harsanyi beneficially owns 7,200 RSUs directly.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive signal, aligning the director's long-term interests with the company's performance and shareholder value. This is a standard and expected compensation practice.

Positives

• The grant of Restricted Stock Units aligns the director's long-term interests with the company's performance and shareholder value.
• Equity-based compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in full on August 6, 2026, which is the first anniversary of the grant date.

Industry Context

The grant of Restricted Stock Units to a director is a common form of equity compensation within the biotechnology and pharmaceutical industries, designed to incentivize long-term commitment and align leadership interests with company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a standard and widely adopted compensation practice within the biotechnology and pharmaceutical sectors.
• This approach is consistent with corporate governance best practices aimed at aligning director incentives with long-term shareholder interests.
• While this filing does not provide specific comparable company data or project results, the use of equity-based compensation like RSUs is a common feature in director compensation packages across companies of similar size and stage in the industry.

Related Party Transactions

• Grant of 7,200 Restricted Stock Units to Zsolt Harsanyi, a Director of Aptevo Therapeutics Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The Restricted Stock Units are scheduled to vest in full on August 6, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice aimed at aligning management interests with shareholder value. While positive, it does not provide sufficient new information to alter an existing investment thesis or warrant a strong buy/sell recommendation. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Aptevo Therapeutics, APVO, Zsolt Harsanyi, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant